121 related articles for article (PubMed ID: 15044053)
1. The combination of metformin and a dipeptidyl peptidase IV inhibitor prevents 5-fluorouracil-induced reduction of small intestine weight.
Yamazaki K; Yasuda N; Inoue T; Nagakura T; Kira K; Saeki T; Tanaka I
Eur J Pharmacol; 2004 Mar; 488(1-3):213-8. PubMed ID: 15044053
[TBL] [Abstract][Full Text] [Related]
2. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds.
Yasuda N; Inoue T; Nagakura T; Yamazaki K; Kira K; Saeki T; Tanaka I
Biochem Biophys Res Commun; 2002 Nov; 298(5):779-84. PubMed ID: 12419322
[TBL] [Abstract][Full Text] [Related]
3. Metformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptidyl peptidase IV inhibitor in Zucker fa/fa rats.
Yasuda N; Inoue T; Nagakura T; Yamazaki K; Kira K; Saeki T; Tanaka I
J Pharmacol Exp Ther; 2004 Aug; 310(2):614-9. PubMed ID: 15039452
[TBL] [Abstract][Full Text] [Related]
4. Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition.
Nagakura T; Yasuda N; Yamazaki K; Ikuta H; Tanaka I
Metabolism; 2003 Jan; 52(1):81-6. PubMed ID: 12524666
[TBL] [Abstract][Full Text] [Related]
5. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV.
Drucker DJ; Shi Q; Crivici A; Sumner-Smith M; Tavares W; Hill M; DeForest L; Cooper S; Brubaker PL
Nat Biotechnol; 1997 Jul; 15(7):673-7. PubMed ID: 9219272
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice.
Hartmann B; Thulesen J; Kissow H; Thulesen S; Orskov C; Ropke C; Poulsen SS; Holst JJ
Endocrinology; 2000 Nov; 141(11):4013-20. PubMed ID: 11089531
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of glucagon-like peptide-2 in pigs: role of dipeptidyl peptidase IV.
Hansen L; Hare KJ; Hartmann B; Deacon CF; Ugleholdt RK; Plamboeck A; Holst JJ
Regul Pept; 2007 Feb; 138(2-3):126-32. PubMed ID: 17107718
[TBL] [Abstract][Full Text] [Related]
8. Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1.
Hinke SA; Kühn-Wache K; Hoffmann T; Pederson RA; McIntosh CH; Demuth HU
Biochem Biophys Res Commun; 2002 Mar; 291(5):1302-8. PubMed ID: 11883961
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1.
Migoya EM; Bergeron R; Miller JL; Snyder RN; Tanen M; Hilliard D; Weiss B; Larson P; Gutierrez M; Jiang G; Liu F; Pryor KA; Yao J; Zhu L; Holst JJ; Deacon C; Herman G; Thornberry N; Amatruda J; Williams-Herman D; Wagner JA; SinhaRoy R
Clin Pharmacol Ther; 2010 Dec; 88(6):801-8. PubMed ID: 21048706
[TBL] [Abstract][Full Text] [Related]
10. Exogenous glucagon-like peptide-2 (GLP-2) prevents chemotherapy-induced mucositis in rat small intestine.
Kissow H; Viby NE; Hartmann B; Holst JJ; Timm M; Thim L; Poulsen SS
Cancer Chemother Pharmacol; 2012 Jul; 70(1):39-48. PubMed ID: 22729158
[TBL] [Abstract][Full Text] [Related]
11. DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cells.
Masur K; Schwartz F; Entschladen F; Niggemann B; Zaenker KS
Regul Pept; 2006 Dec; 137(3):147-55. PubMed ID: 16908079
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes.
Lindsay JR; Duffy NA; McKillop AM; Ardill J; O'Harte FP; Flatt PR; Bell PM
Diabet Med; 2005 May; 22(5):654-7. PubMed ID: 15842525
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell.
Mulherin AJ; Oh AH; Kim H; Grieco A; Lauffer LM; Brubaker PL
Endocrinology; 2011 Dec; 152(12):4610-9. PubMed ID: 21971158
[TBL] [Abstract][Full Text] [Related]
14. ASP8497 is a novel selective and competitive dipeptidyl peptidase-IV inhibitor with antihyperglycemic activity.
Matsuyama-Yokono A; Tahara A; Nakano R; Someya Y; Nagase I; Hayakawa M; Shibasaki M
Biochem Pharmacol; 2008 Jul; 76(1):98-107. PubMed ID: 18468582
[TBL] [Abstract][Full Text] [Related]
15. A novel DPP-IV-resistant analog of glucagon-like peptide-1 (GLP-1): KGLP-1 alone or in combination with long-acting PLGA microspheres.
Gao Z; Tang Y; Chen J; Bai R; Zhang Q; Hou Y; Lu Y; Bai G
Peptides; 2009 Oct; 30(10):1874-81. PubMed ID: 19647775
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide-2 and common therapeutics in a murine model of ulcerative colitis.
L'Heureux MC; Brubaker PL
J Pharmacol Exp Ther; 2003 Jul; 306(1):347-54. PubMed ID: 12815012
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide-1 derivatives and dipeptidyl peptidase-IV inhibitors. New hope for the treatment of type-2 diabetes.
Al-Omar MA; Al-Arifi MN
Saudi Med J; 2005 Oct; 26(10):1511-5. PubMed ID: 16228047
[TBL] [Abstract][Full Text] [Related]
18. Newly approved and promising antidiabetic agents.
Combettes M; Kargar C
Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
[TBL] [Abstract][Full Text] [Related]
19. The role of polyamines in glucagon-like peptide-2 prevention of TPN-induced gut hypoplasia.
Chance WT; Sheriff S; Dayal R; Friend LA; Thomas I; Balasubramaniam A
Peptides; 2006 Apr; 27(4):883-92. PubMed ID: 16274854
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice.
Kim SJ; Nian C; Doudet DJ; McIntosh CH
Diabetes; 2008 May; 57(5):1331-9. PubMed ID: 18299314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
